

Roman Kloeckner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/235456/publications.pdf>

Version: 2024-02-01

52
papers

1,581
citations

471509

17
h-index

330143

37
g-index

53
all docs

53
docs citations

53
times ranked

2054
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. <i>Cancer Treatment Reviews</i> , 2019, 72, 28-36.	7.7	342
2	MDCT Versus MRI Assessment of Tumor Response After Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2010, 33, 532-540.	2.0	110
3	Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. <i>BMC Cancer</i> , 2015, 15, 465.	2.6	105
4	Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 352-360.	2.0	95
5	Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. <i>Journal of Hepatology</i> , 2021, 74, 1362-1372.	3.7	74
6	How COVID-19 kick-started online learning in medical educationâ€”The DigiMed study. <i>PLoS ONE</i> , 2021, 16, e0257394.	2.5	74
7	Local and Regional Therapies for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 137-149.	7.3	69
8	Radiation exposure in CT-guided interventions. <i>European Journal of Radiology</i> , 2013, 82, 2253-2257.	2.6	67
9	Survival analysis of proposed <sc>BCLC</sc> subgroups in hepatocellular carcinoma patients. <i>Liver International</i> , 2015, 35, 591-600.	3.9	60
10	Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?. <i>Liver International</i> , 2019, 39, 324-331.	3.9	55
11	Joint Imaging Platform for Federated Clinical Data Analytics. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 1027-1038.	2.1	39
12	Attitudes Toward Artificial Intelligence Among Radiologists, IT Specialists, and Industry. <i>Academic Radiology</i> , 2020, 28, 834-840.	2.5	39
13	Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 94-102.	0.5	34
14	Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study. <i>Liver International</i> , 2020, 40, 694-703.	3.9	32
15	Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 403-419.	3.7	25
16	Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 311.	1.6	24
17	CIRSE Clinical Practice Manual. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1323-1353.	2.0	24
18	The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?. <i>Liver International</i> , 2019, 39, 1307-1314.	3.9	20

#	ARTICLE	IF	CITATIONS
19	Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2017, 40, 1017-1025.	2.0	17
20	Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?. Frontiers in Oncology, 2021, 11, 696183.	2.8	17
21	Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma. BMC Cancer, 2018, 18, 489.	2.6	16
22	Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers, 2021, 13, 5018.	3.7	16
23	Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC. European Radiology, 2022, 32, 6302-6313.	4.5	13
24	Transjugular intrahepatic portosystemic shunt (TIPS) dysfunction: quantitative assessment of flow and perfusion changes using 2D-perfusion angiography following shunt revision. Abdominal Radiology, 2018, 43, 2868-2875.	2.1	12
25	Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads. Abdominal Radiology, 2018, 43, 1245-1253.	2.1	12
26	Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United European Gastroenterology Journal, 2022, 10, 41-53.	3.8	12
27	Distant Metastases in Patients with Intrahepatic Cholangiocarcinoma: Does Location Matter? A Retrospective Analysis of 370 Patients. Journal of Oncology, 2020, 2020, 1-8.	1.3	11
28	Endovascular simulation training: a tool to increase enthusiasm for interventional radiology among medical students. European Radiology, 2020, 30, 4656-4663.	4.5	11
29	The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS ONE, 2021, 16, e0249426.	2.5	11
30	Online teaching in radiology as a pilot model for modernizing medical education: results of an international study in cooperation with the ESR. Insights Into Imaging, 2021, 12, 141.	3.4	11
31	Quantitative assessment of washout in hepatocellular carcinoma using MRI. BMC Cancer, 2016, 16, 758.	2.6	10
32	Fluoroscopy-guided Hepaticojejunosomy in Recurrent Anastomotic Stricture after Repeated Surgical Hepaticojejunosomy. Journal of Vascular and Interventional Radiology, 2013, 24, 1750-1752.	0.5	9
33	Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) with Melphalan: Evaluation of 2D-Perfusion Angiography (2D-PA) for Leakage Detection of the Venous Double-Balloon Catheter. CardioVascular and Interventional Radiology, 2019, 42, 1441-1448.	2.0	9
34	Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imaging. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1883-1890.	2.5	9
35	Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance. United European Gastroenterology Journal, 2021, 9, 590-597.	3.8	9
36	Evaluation of a Motion Correction Algorithm for C-Arm Computed Tomography Acquired During Transarterial Chemoembolization. CardioVascular and Interventional Radiology, 2021, 44, 610-618.	2.0	8

#	ARTICLE	IF	CITATIONS
37	The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2732.	2.4	8
38	Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. <i>Cancers</i> , 2022, 14, 2469.	3.7	8
39	Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. <i>Cancers</i> , 2021, 13, 3961.	3.7	7
40	Liver Resection for Intrahepatic Cholangiocarcinoma—Single-Center Experience with 286 Patients Undergoing Surgical Exploration over a Thirteen Year Period. <i>Journal of Clinical Medicine</i> , 2021, 10, 3559.	2.4	7
41	Transjugular Portosystemic Stent Shunt: Impact of Right Atrial Pressure on Portal Venous Hemodynamics Within the First Week. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 102-111.	2.0	7
42	Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems. <i>Frontiers in Oncology</i> , 2022, 12, 850454.	2.8	7
43	Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. <i>JHEP Reports</i> , 2022, 4, 100417.	4.9	6
44	Risk prediction in intrahepatic cholangiocarcinoma: Direct comparison of the MEGNA score and the 8th edition of the UICC/AJCC Cancer staging system. <i>PLoS ONE</i> , 2020, 15, e0228501.	2.5	5
45	Survival Prediction in Intrahepatic Cholangiocarcinoma: A Proof of Concept Study Using Artificial Intelligence for Risk Assessment. <i>Journal of Clinical Medicine</i> , 2021, 10, 2071.	2.4	5
46	Transarterial chemoembolization for hepatocellular carcinoma: quality of life, tumour response, safety and survival comparing two types of drug-eluting beads. <i>Abdominal Radiology</i> , 2020, 45, 3326-3336.	2.1	4
47	Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	4
48	High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2021, 9, 388-397.	3.8	4
49	Reply to: "Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?" <i>Journal of Hepatology</i> , 2021, 75, 489-490.	3.7	3
50	Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?. <i>Cancer Imaging</i> , 2022, 22, 5.	2.8	3
51	Myocardial Mass Corrected CMR Feature Tracking-Based Strain Ratios are Different in Pathologies With Increased Myocardial Mass. <i>Academic Radiology</i> , 2020, , .	2.5	2
52	Integrative Analysis of Intrahepatic Cholangiocarcinoma Subtypes for Improved Patient Stratification: Clinical, Pathological, and Radiological Considerations. <i>Cancers</i> , 2022, 14, 3156.	3.7	0